Sight Sciences, Inc. (SGHT)

Market Cap	273.68M +74.7%
Revenue (ttm)	79.55M +1.8%
Net Income	-37.25M
EPS	-0.71
Shares Out	54.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,607
Open	5.19
Previous Close	5.14
Day's Range	4.97 - 5.23
52-Week Range	3.11 - 9.24
Beta	2.37
Analysts	Buy
Price Target	8.34 (+65.81%)
Earnings Date	May 6, 2026

About SGHT

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and O...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 186
• Stock Exchange: NASDAQ
• Ticker Symbol: SGHT
• Website: https://www.sightsciences.com

Financial Performance

In 2025, Sight Sciences's revenue was $77.36 million, a decrease of -3.13% compared to the previous year's $79.87 million. Losses were -$38.43 million, -25.40% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price target is $8.34, which is an increase of 65.81% from the latest price.

Price Target

$8.34

(65.81% upside)

Analyst Consensus: Buy